Mylan (MYL) Stock Research, Analysis & News

Quick Analysis on Mylan (MYL) Stock as of January 28, 2020

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Mylan (MYL) Stock below)

Mylan (MYL) Stock Profile Summary

Mylan Inc. and its subsidiaries engage in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment offers generic or branded generic pharmaceutical products in tablet, capsule, or transdermal patch form, as well as APIs. This segment markets its products for the proprietary and ethical pharmaceutical wholesalers and distributors, drug store chains, drug manufacturers, institutions, and public and governmental agencies located primarily in the United States and Canada, Europe, the Middle East, Africa, Australia, Japan, India, and New Zealand. The Specialty segment provides branded specialty nebulized, injectable, and transdermal products for life-threatening conditions. Its principal products comprise EpiPen that is used for the treatment of severe allergies; and Perforomist Inhalation Solution, a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease patients. This segment markets its products to the pharmaceutical wholesalers and distributors located primarily in the United States. Additionally, Mylan manufactures and supplies APIs for the manufacture of anti-retroviral (ARV) drugs, which are utilized in the treatment of HIV/AIDS; and offers a line of finished dosage form (FDF) products in both the ARV and non-ARV markets. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan was founded in 1961 and is based in Canonsburg, Pennsylvania.

Mylan (MYL) Stock Key Statistics Research and Analysis as of January 28, 2020

Mylan (MYL) Stock Competitor Research and Analysis

Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
Amgen Inc. (AMGN)Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)King Pharmaceuticals Inc. (KG)
Pfizer Inc. (PFE)Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)Sanofi-Aventis (SNY)
Novartis AG (NVS)

Mutual Funds with Mylan (MYL) Stock in its top 10 holdings

FundCategoryMYL Holding Percentage
AllianzGI Health Sciences DHealth2.75%
Transamerica Partners Instl Mid GrMid-Cap Growth2.88%
Hartford Value Opportunities ALarge Value2.45%
ProFunds Pharmaceuticals UltraSector InvTrading--Leveraged Equity1.37%

ETFs with Mylan (MYL) Stock in its top 10 holdings

Stock Research on Mylan (MYL)

Latest Market News on Mylan (MYL)

Click here to find the latest news on Mylan (MYL)

Looking for Market Opportunties?

Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
King Pharmaceuticals Inc. (KG)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)